Stent for liberating drug

• US 5,733,327 A
• Filed: 06/14/1996
• Issued: 03/31/1998
• Est. Priority Date: 10/17/1994
• Status: Expired due to Term

• Current Assignee: Hideo Tamai, Keiji Igaki
• Original Assignee: Hideo Tamai, Keiji Igaki
• Inventors: Igaki, Keiji, Tamai, Hideo
• Primary Examiner(s): Milano, Michael J.
• Assistant Examiner(s): NGUYEN, TRAM A
• Application Number:
  US08/663,173
• Time in Patent Office: 655 Days
• Field of Search: 623/1, 623/11, 623/12, 606/194, 606/198
• US Class Current: 623/1.5
• CPC Class Codes: A61F 2/86 Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2/90 characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2230/005 Rosette-shaped, e.g. star-shaped
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

A stent according to the present invention is adapted to be introduced into a vascular system such as blood vessels. The stent includes a stent body produced by weaving or knitting a fiber containing a drug and made of a low-melting biodegradable polymer into a tubular shape, or coating a drug-containing low-melting biodegradable polymer on a stent body. When the stent is introduced into the vascular system, the drug contained therein is dosed in a locally limited region of the vascular system. The low-melting biodegradable polymer used has a melting point of 80° C. or lower and is at least one compound selected from the group consisting of poly-ε-caprolactone, poly-D, L-deca-lactone, poly-dioxane and a copolymer thereof.

Claims

1. A stent for liberating TRANIRAST, which is adapted to be introduced into a vascular system such as blood vessels, comprising a stent body produced by weaving or knitting into a tubular shape a fiber containing TRANIRAST and made of a low-melting biodegradable polymer having a melting point at which no pharmacological effects of TRANIRAST are damaged.

2. A stent for eluting TRANIRAST contained therein, comprising a stent body coated with a mixture composed of TRANIRAST and a low-melting biodegradable polymer having a melting point at which no pharmacological effects of TRANIRAST are damaged.

3. A stent for liberating a drug, which is adapted to be introduced into a vascular system such as blood vessels, comprising:

a stent body produced by weaving or knitting into a tubular shape a composite fiber composed of fiber made of a low-melting biodegradable polymer having a melting point at which no pharmacological effects of the druq are damaged and a fiber made of a high-melting biodegradable polymer having a melting point higher than that of the fiber composed of the low-melting biodegradable polymer;

wherein the low-melting biodegradable polymer exposed to an outer surface of the stent body is heat-fused to smoothen the outer surface;

wherein the high-melting biodegradable polymer is at least compound selected from the group consisting of poly-lactic acid, polyglycolic acid and a copolymer thereof;

wherein the melting point of the low-melting point biodegradable polymer is 80°

C. or lower; and

wherein the composite fiber constituting the stent body is a two folded yarn, the two folded yarn including a TRANIRAST-containing poly-ε

-caprolactone fiber.